INVO Fertility, Inc (NASDAQ:IVF) Sees Large Decrease in Short Interest

INVO Fertility, Inc (NASDAQ:IVF) was the target of a significant decline in short interest during the month of October. As of October 15th, there was short interest totaling 26,478 shares, a decline of 47.2% from the September 30th total of 50,118 shares. Approximately 1.1% of the company’s stock are sold short. Based on an average daily trading volume, of 140,470 shares, the short-interest ratio is presently 0.2 days.

INVO Fertility Stock Performance

NASDAQ IVF traded down $0.23 during trading hours on Friday, hitting $1.91. The company’s stock had a trading volume of 129,525 shares, compared to its average volume of 114,523. INVO Fertility has a 12 month low of $1.59 and a 12 month high of $106.32. The company’s 50 day simple moving average is $13.26 and its two-hundred day simple moving average is $37.03. The company has a debt-to-equity ratio of 0.03, a current ratio of 0.71 and a quick ratio of 0.67. The company has a market cap of $4.79 million, a P/E ratio of -0.06 and a beta of 2.39.

INVO Fertility (NASDAQ:IVF) last posted its earnings results on Friday, August 14th. The company reported $5.60 earnings per share (EPS) for the quarter. The business had revenue of $2.18 million for the quarter. INVO Fertility had a negative net margin of 116.29% and a negative return on equity of 85.54%.

Wall Street Analyst Weigh In

IVF has been the topic of several analyst reports. Wall Street Zen upgraded shares of INVO Fertility to a “hold” rating in a research note on Saturday, August 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of INVO Fertility in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, INVO Fertility has a consensus rating of “Moderate Buy” and a consensus price target of $320.00.

About INVO Fertility

INVO Fertility, Inc is a commercial-stage fertility company focused on expanding access to assisted reproductive technology. The company develops and commercializes fertility products and services designed to provide alternatives to conventional in vitro fertilization (IVF) treatment.

Its principal product is INVOcell, a medical device used in the INVO Procedure. The system allows early-stage embryo incubation to take place inside the patient’s body rather than in a conventional laboratory incubator, while still involving the retrieval of eggs, fertilization, and subsequent embryo transfer under the supervision of fertility professionals.

In addition to commercializing INVOcell, INVO Fertility operates and supports fertility centers that provide reproductive services, including IVF and related treatments.